

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet	1	of	1
-------	---	----	---

Complete if Known

Application Number	10/645,085
Filing Date	01/24/2003
First Named Inventor	Naoshii Fukushima
Group Art Unit	1643
Examiner Name	Bristol, Lynn
Attorney Docket Number	065678-0108

U.S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

[illegible]

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
LAB	D1	AVENT et al., "Monoclonal antibodies that recognize different membrane proteins that are deficient in Rh _{null} human erythrocytes," Biochem. J., 1988, vol. 251, pp. 499-505.	
↓	D2	BROWN et al., "Integrin-associated Protein: A 50-kD Plasma Membrane Antigen Physically and Functionally Associated with Integrins," J. Cell Biology, December 1990, vol. 111, no. 6, pt. 1, pp. 2785-2794.	

D3 App. No. 98 941 848.8 (p. 1) date 10.03.2006

LAP

Examiner
Signature

/Lynn Bristol/

Date
Considered

09/20/2006

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

*Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. *Applicant is to place a check mark here if English language translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

Substitute for Form PTO

Complete if Known

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

Date Submitted: March 29, 2006

(use as many sheets as necessary)

Sheet 1 of 5

Application Number 10/645,085
Filing Date 01/24/2003
First Named Inventor Naoshi Fukushima
Group Art Unit 1643
Examiner Name Bristol, Lynn
Attorney Docket Number 065678-0108

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
LAB	C1	5,837,242		Holliger et al.	11-17-1998	
	C2	5,840,344		Fukushima	11-24-1998	
	C3	5,885,574		Elliott	03-23-1999	
	C4	6,719,972	B1	Gribben et al.	04-13-2004	
	C5	6,759,043	B2	Fukushima	07-06-2004	
	C6	6,579,692	B1	Fukushima	06-17-2003	
	C7	2003/0157100	A1	Fukushima et al.	08-2003	
	C8	2003/0211108	A1	Fukushima et al.	11-2003	
	C9	2003/0147894	A1	FUKUSHIMA et al.	08/07/2003	
	C10	2003/0157577	A1	Fukushima et al.	08-2003	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office ³	Number ⁴	Kind Code ⁵ (if known)				
LAB	C11	WO	91/16928		Cell-Tech Limited	11-14-1991		
	C12	WO	96/36360	A	UNIV MINNESOTA	11-21-1996		
	C13	WO	99/03495	A	BETH ISRAEL HOSPITAL	01-28-1999		
	C14	WO	99/10494		Genentech, Inc.	03-04-1999		
	C15	JP	11-092500		Chugai Pharma. Co. Ltd.	04-06-1999		A
	C16	WO	99/17364		Raytheon Company	04-08-1999		
	C17	EP	1 035 132		Chugai Seiyaku Kabushiki Kaisha	09-13-2000		
	C18	WO	02/078612	A	PURDUE PHARMA LP	10-10-2002		

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
LAB	C19	BARTLEY, T., et al., "Identification and Cloning of a Megakaryocyte Growth and Development Factor That is a Ligand for the Cytokine Receptor Mpl," Cell, Vol. 77, pp. 1117-1124 (1994).	
	C20	BAZIL, V., et al., "Apoptosis of Human Hematopoietic Progenitor Cells Induced by Crosslinking of Surface CD43, the Major Sialoglycoprotein of Leukocytes," pp. 502-511 (1995)	

Examiner Signature

/Lynn Bristol/

Date Considered

09/20/2006

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Application Number	10/645,085
		Filing Date	01/24/2003
		First Named Inventor	Naoshi Fukushima
		Group Art Unit	1643
		Examiner Name	Bristol, Lynn
Date Submitted: March 29, 2006		Attorney Docket Number	065678-0108
(use as many sheets as necessary)			
Sheet	2	of	5

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
LAB	C21	BERGER, S. L., et al., "Inhibition of Intractable Nucleases with Ribonucleoside-Vanadyl Complexes: Isolation of Messenger Ribonucleic Acid From Resting Lymphocytes", <i>Biochemistry</i> , Vol. 18, No. 23, pp. 5143-5149 (1979)	
	C22	BURTHEM, et al., "Hairy Cell Interactions with Extracellular Matrix: Expression of Specific Integrin Receptors and Their Role in the Cell's Response to Specific Adhesive Proteins," <i>Blood</i> , Vol. 84, No. 3, pp. 873-882 (1994).	
	C23	CALDAS, C., et al., <i>Mol. Immunol.</i> , Vol. 39, No. 15, pp. 941-952 (2003).	
	C24	CHIEN, N. C., et al., <i>Proc. Natl. Acad. Sci. USA</i> , Vol. 84, No. 14, pp. 5532-5536 (1989).	
	C25	CHIRGWIN, J. M., et al., "Isolation of Biologically Active Ribonucleic Acid from Sources Enriched in Ribonuclease", <i>Biochemistry</i> , Vol. 18, No. 24, pp. 5294-5299 (1979).	
	C26	COOPER, D., et al., "Transendothelial migration of neutrophils involves integrin-associated protein (CD47)," <i>Proc. Natl. Acad. Sci. USA</i> , pp. 3978-3982 (1995).	
	C27	de SAUVAGE, F., et al., "Stimulation of Megakaryocytopoiesis and Thrombopoiesis by the c-Mpl Ligand," <i>Nature</i> , Vol. 369, pp. 533-538 (1994).	
	C28	de ST. GROTH, S. F., et al., "Production of Monoclonal Antibodies: Strategy and Tactics," <i>Journal of Immunological Methods</i> , Vol. 35, pp. 1-21 (1980)	
	C29	DENG, B., et al., "An Agonist Murine Monoclonal Antibody to the Human c-Mpl Receptor Stimulates Megakaryocytopoiesis," <i>Blood</i> , Vol. 92, No. 6, pp. 1981-1988 (1991).	
	C30	FELGENHAUER, M., et al., "Nucleotide Sequences of the cDNAs Encoding the V-Regions of H- and L-Chains of a Human Monoclonal Antibody Specific to HIV-1 - gp41," <i>Nucleic Acids Research</i> , Vol. 18, No. 16, p. 4927 (1990).	
	C31	FUJIMOTO, T., et al., <i>Blood</i> , Vol. 86, No. 6, pp. 2174-2182 (1995).	
	C32	FUKUSHIMA, N., et al., "Enhanced Hematopoiesis In Vivo and In Vitro by Splenic Stromal Cells Derived From the Mouse With Recombinant Granulocyte Colony-Stimulating Factor", <i>Blood</i> , Vol. 80, No. 8, pp. 1914-1922 (1992)	
	C33	GALFRE, G., et al., "Preparation of Monoclonal Antibodies: Strategies and Procedures," <i>Methods in Enzymology</i> , Vol. 73, pp. 3-46 (1981)	
	C34	GALFRE, G., et al., "Rat x rat hybrid myelomas and a monoclonal anti-Fd portion of mouse IgG," <i>Nature</i> , Vol. 277, pp. 131-133 (1979)	
	C35	GENESTIER, L., et al., "Antibodies to HLA Class I α 1 Domain Trigger Apoptosis of CD 40-Activated Human B Lymphocytes," <i>Blood</i> , Vol. 90, No. 2, pp. 726-735 (1997)	

Examiner Signature	/Lynn Bristol/	Date Considered	09/20/2006
--------------------	----------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT Date Submitted: March 29, 2006 (use as many sheets as necessary)		Application Number	10/645,085
		Filing Date	01/24/2003
		First Named Inventor	Naoshi Fukushima
		Group Art Unit	1643
		Examiner Name	Bristol, Lynn
Sheet	3	of	5
		Attorney Docket Number	065678-0108

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
LAB	C36	GIUSTI, A. M., et al., Proc. Natl. Acad. Sci. USA, Vol. 84, No. 9, pp. 2926-2930 (1987).	
	C37	GODING, Monoclonal Antibodies: Principles and Practice, Academic Press, second Ed, pp. 125-129 (1986)	
	C38	GRELL, M., et al., "TR50 and TR80 Tumor Necrosis Factor (TNF)-Receptors Can Independently Mediate Cytolysis", Lymphokine and Cytokine Research, vol. 12, no. 3, pp. 143-148 (June 1993).	
	C39	GUSSOW, D., et al., Methods in Enzymology, Vol. 203, pp. 99-121 (1991).	
	C40	HOPP, T., et al., "A Short Polypeptide Marker Sequence Useful for Recombinant Protein Identification and Purification," Bio/Technology, Vol. 6, pp. 1204-1210 (1988).	
	C41	HUDSON, P. J., et al., "High avidity scFv multimers; diabodies and triabodies" J. Immunol. Methods, Elsevier Science Publishers, Vol. 231, No. 1-2, pp. 177-189 (1999).	
	C42	HUSTON, J., et al., "Protein Engineering of Antibody Binding Sites: Recovery of Specific Activity in an Anti-Digoxin Single-Chain Fv Analogue Produced in <i>Escherichia Coli</i> ," Proc. Natl. Acad. Sci. USA, Vol. 85, pp. 5879-5883 (1988).	
	C43	ITOH, N., et al., "The Polypeptide Encoded by the cDNA for Human Cell Surface Antigen Fas Can Mediate Apoptosis," Cell, Vol. 66, pp. 233-243 (1991)	
	C44	JIANG et al., "A Novel Peptide Isolated from a Phage Display Peptide Library with Trastuzumab Can Mimic Antigen Epitope of HER-2," J. Biol. Chem., February 11, 2005, Vol. 280, No. 6, pp. 4656-4662.	
	C45	KEARNEY, J. F., et al., "A New Mouse Myeloma Cell Line That Has Lost Immunoglobulin Expression But Permits The Construction of Antibody-Secreting Hybrid Cells Lines," The Journal of Immunology, Vol. 123, No. 4, pp. 1548-1550 (1979)	
	C46	KIPRIYANOV, S., et al., "Bispecific CD3 X CD19 Diabody for T Cell-Mediated Lysis of Malignant Human B Cells," Int. J. Cancer, Vol. 77, pp. 763-772 (1988).	
	C47	KOHLER, G., et al., "Derivation of specific antibody-producing tissue culture and tumor lines by cell fusion," Eur. J. Immunol., Vol. 6, pp. 511-519 (1976)	
	C48	LARRICK, J. W., et al., "Polymerase Chain Reaction Using Mixed Primers: Cloning of Human Monoclonal Antibody Variable Region Genes From Single Hybridoma Cells", Bio/Technology, Vol. 7, pp. 934-938 (1989)	
	C49	LAW, L. W., et al., "Observations On The Effect Of A Folic-Acid Anatagonist On Transplantable Lymphoid Leukemias In Mice", Journal of the National Cancer Institute, Vol. 10, pp. 179-193 (1949).	
	C50	LEI, S. et al., "Characterization of the <i>Erwinia Carotovora pelB</i> Gene and Its Product Pectate Lyase," J. Bacteriol., pp. 4379-4383 (1987).	
	C51	LINDBERG, et al., "Rh-Related Antigen CD47 is the Signal-Transducer Integrin-Associated Protein," J. Biol. Chem., Vol. 269, pp. 1567-1570 (1994).	

Examiner Signature	/Lynn Bristol/	Date Considered	09/20/2006
--------------------	----------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT Date Submitted: March 29, 2006 (use as many sheets as necessary)				Application Number	10/645,085
				Filing Date	01/24/2003
				First Named Inventor	Naoshi Fukushima
				Group Art Unit	1643
				Examiner Name	Bristol, Lynn
Sheet	4	of	5	Attorney Docket Number	065678-0108

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶	
LAB	C52	MARGULIES, D. H., et al., "Somatic Cell Hybridization of Mouse Myeloma Cells," Cell, Vol. 8, pp. 405-415 (1976)		
	C53	MARIUZZA, R. A., et al., Annu. Rev. Biophys. Biophys. Chem., Vol. 16, pp. 139-159 (1987)		
	C54	MAWBY, W. J., et al., "Isolation and characterization of CD47 glycoprotein: a multispanning membrane protein which is the same as integrin-associated protein (IAP) and the ovarian tumor marker OA3," Biochem. J., Vol. 304, pp. 525-530 (1994)		
	C55	METHIA, N., et al., "Oligodeoxynucleotides Antisense to the Proto-Oncogene <i>c-Mpl</i> Specifically Inhibit In Vitro Megakaryocytopoiesis," Blood, Vol. 82, No. 5, pp. 1395-1401 (1993).		
	C56	MILILI, M., et al., "The VDJ Repertoire Expressed in Human preB Cells Reflects the Selection of <i>Bona Fide</i> Heavy Chains," Eur. J. Immunol., Vol. 26, pp. 63-69 (1996).		
	C57	NAKAYAMA, et al., J. Mole. Med., Vol. 83, PP. 316-320 (2005).		
	C58	PAUL, Fundamental Immunology, Raven Press, NY, Chapter 8, p. 242 (1993)		
	C59	PETTERSON, "CD47 and death signaling in the immune system," Apoptosis Vol. 5, pp. 299-306 (2000)		
	C60	REINHOLD et al., "In vivo expression of alternatively spliced forms of integrin-associated protein (CD47)," J. Cell Science, 1995, vol. 108, pp. 3419-3425.		
	C61	RIECHMANN, L., et al., "Reshaping Human Antibodies for Therapy", Nature, Vol. 332, pp. 323-327 (1988).		
	C62	ROUE, G., et al., Biochimie, Vol. 85, pp. 741-746 (2003).		
	C63	RUDIHOFF, et al., Proc. Natl. Acad. Sci. USA Vol. 79, p. 1979 (1982)		
	C64	SCHICKEL, et al., "Gene for Integrin-Associated Protein (IAP, CD47): Physical Mapping, Genomic Structure, and Expression Studies in Skeletal Muscle," Biochem. Cell. Biol., Vol. 80, No. 2, pp. 169-176 (2002).		
	C65	SCHWARTZ, M. A., et al., "A 50-kDa Integrin-associated Protein Is Required for Integrin-regulated Calcium Entry in endothelial Cells," J. Biol. Chem., Vol. 268, No. 27, pp. 19931-19934 (1993)		
	C66	SHIGETA, M., et al., "Sperm-immobilizing monoclonal antibody to human seminal plasma antigens," Clin. Exp. Immunol., Vol. 42, pp. 458-462 (1980)		
	C67	SHULMAN, M., et al., "A better cell line for making hybridomas secreting specific antibodies," Nature, Vol. 276, pp. 269-270 (1978)		
	C68	SKOLNICK, et al., "From Genes to Protein Structure and Function: Novel Applications of Computational Approaches in the Genomic Era," Trends in Biotechnology, Vol. 18, pp. 34-39 (2000).		

Examiner Signature	/Lynn Bristol/	Date Considered	09/20/2006
--------------------	----------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT Date Submitted: March 29, 2006 (use as many sheets as necessary)				Application Number	10/645,085
				Filing Date	01/24/2003
				First Named Inventor	Naoshi Fukushima
				Group Art Unit	1643
				Examiner Name	Bristol, Lynn
Sheet	5	of	5	Attorney Docket Number	065678-0108

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.		T ⁶
LAB ↓	C69	SOUYRI, M., et al., "A Putative Truncated Cytokine Receptor Gene Transduced by the Myeloproliferative Leukemia Virus Immortalizes Hematopoietic Progenitors," Cell, Vol. 63, December 21, pp. 1137-1147 (1990).		
	C70	SPAARGAREN, M., et al., "Antibody-induced Dimerization Activates the Epidermal Growth Factor Receptor Tyrosine Kinase", The J. Biol. Chem., Vol. 266, No. 3, pp. 1733-1739 (1981).		
	C71	STANCOVSKI et al., "Mechanistic aspects of the opposing effects of monoclonal antibodies to the ERBB2 receptor on tumor growth," Proc. Natl. Acad. Sci. USA, October 1991, Vol. 88, pp. 8691-8695.		
	C72	TROWBRIDGE, I. S., "Interspecies Spleen-Myeloma Hybrid Producing Monoclonal Antibodies Against Mouse Lymphocyte Surface Glycoprotein, T200," J. Exp. Med., Vol. 148, pp. 313-323 (1978)		
	C73	XIE, et al, "Direct demonstration of MuSK involvement in acetylcholine receptor clustering through identification of agonist ScFv," Nature Biotechnology, Vol. 15, pp. 768-771 (1997).		
	C74	YELTON, D. E., et al., "Fusion of Mouse Myeloma and Spleen Cells," Current Topics in Microbiology and Immunology, Vol. 81, pp. 1-7 (1978)		

Examiner Signature	/Lynn Bristol/	Date Considered	09/20/2006
--------------------	----------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.